

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

IN RE:
BRIMONIDINE PATENT LITIGATION

C.A. 07-md-01866 GMS

**NOTICE OF DEPOSITION OF DEFENDANT EXELA PHARMSCI, INC. PURSUANT
TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6)**

PLEASE TAKE NOTICE that, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Plaintiff Allergan Inc. (“Plaintiff”) by its counsel, will take the deposition of Defendant Exela Pharmsci, Inc. (“Defendant”) at the offices of Fish & Richardson P.C., 919 N. Market Street, Suite 1100, Wilmington, Delaware 19899, commencing at 9:00 a.m. on May 27, 2008, or at such other place and time as may be agreed upon by counsel. The deposition will continue from day to day until completed. Some or all of the deposition testimony may be recorded by stenographic, audio, audiovisual, video, and/or real-time computer means.

The subject matters of the deposition are enclosed herein. Pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Defendant is obligated to designate one or more officers, directors, managing agents, or other persons who consent to testify on its behalf concerning the matters set forth in the attached Appendix. Plaintiff requests that Defendant provide, on or before May 21, 2008, a written designation of the names and positions of the officers, directors, or other persons who are most competent to testify concerning the topics set forth below, and for each person designated, the matters on which he or she will testify.

DEFINITIONS

The definitions set forth in Plaintiff's First Set of Interrogatories shall apply as if fully set forth herein.

RULE 30(b)(6) TOPICS FOR DEPOSITION

1. Defendant's organizational structure.
2. Defendant's corporate structure.
3. Defendant's relationship to and interactions with the other defendants in this lawsuit.
4. Defendant's role in the development of the proposed brimonidine product.
5. The formulation of Defendant's proposed brimonidine product.
6. The development of Defendant's proposed brimonidine product.
7. The intended use of Defendant's proposed brimonidine product.
8. All testing of Defendant's proposed brimonidine product, or any formulations employed in the development of Defendant's proposed brimonidine product, or any components of Defendant's proposed brimonidine product.
9. Defendant's ANDA No. 78-590.
10. Defendant's interactions with the FDA regarding Defendant's proposed brimonidine product, ANDA No. 78-590 and/or Allergan's ALPHAGAN 0.15% product, including all communications with the FDA regarding ANDA No. 78-590 and/or Allergan's ALPHAGAN P 0.15% product.
11. Any Clinical Trials for ANDA No. 78-590 or defendant's proposed brimonidine product.
12. Any Bioequivalence and/or bioavailability Testing for ANDA No. 78-590 or defendant's proposed brimonidine product.

13. The alleged therapeutic equivalence of defendant's proposed brimonidine product to Allergan's ALPHAGAN P 0.15%.

14. Each ingredient in Defendant's proposed brimonidine product, its function(s) in the formulation and the reasons(s) why such ingredient included in the formulation.

15. All testing of Allergan's ALPHAGAN products.

16. The differences between Defendant's proposed brimonidine product and Allergan's ALPHAGAN P .15%.

17. When Defendant became aware of U.S. Patent No. 6,641,834 ("the '834 patent").

18. Defendant's knowledge of the '834 patent.


19. Defendant's experience with and/or knowledge of the ophthalmic industry.

20. Defendant's business reasons for developing and filing ANDA No. 78-590.

21. Defendant's interactions with doctors and/or healthcare professionals with regard to the proposed brimonidine product or potential brimonidine based ophthalmic products.

Dated: May 5, 2008

FISH & RICHARDSON P.C.

By: 
William J. Marsden, Jr. (#2247)
Susan M. Coletti (#4690)
919 N. Market Street, Suite 1100
P.O. Box 1114
Wilmington, DE 19899-1114
Telephone: (302) 652-5070
Email: marsden@fr.com

Of Counsel:

Jonathan E. Singer
Michael J. Kane
Deanna J. Reichel
FISH & RICHARDSON P.C.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070

Juanita Brooks
FISH & RICHARDSON P.C.
12390 El Camino Real
San Diego, CA 92130
Telephone: (858) 678-5070

W. Chad Shear
FISH & RICHARDSON P.C.
1717 Main St., Suite 5000
Dallas, TX 75201
Telephone: (214) 747-5070

**ATTORNEYS FOR PLAINTIFF
ALLERGAN, INC.**

60491665.doc

CERTIFICATE OF SERVICE

I hereby certify that on May 5, 2008, I electronically filed with the Clerk of Court the NOTICE OF DEPOSITION OF DEFENDANT EXELA PHARMSCI, INC. PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6) using CM/ECF which will send electronic notification of such filing(s) to the following counsel.

VIA EMAIL AND FEDERAL EXPRESS

Walter J. Kawula
Sherry Rollo
Welsh & Katz, Ltd.
120 South Riverside Plaza, 22nd Floor
Chicago, IL 60606

VIA EMAIL AND HAND DELIVERY

Frederick L. Cottrell, III
Kelly E. Farnan
Richard, Layton & Finger
One Rodney Square
Wilmington, DE 19899

VIA EMAIL AND FEDERAL EXPRESS

Roderick G. Dorman
Hennigan, Bennett & Dorman LLP
865 South Figueroa Street, Suite 2900
Los Angeles, CA 90017

VIA EMAIL AND HAND DELIVERY


Richard L. Horwitz
Potter Anderson & Corroon LLP
Hercules Plaza
1313 North Market Street, 6th Floor
Wilmington, DE 19899

VIA EMAIL AND FEDERAL EXPRESS

Daniel G. Brown
Arthur L. Hoag
David A. Zwally
Brian J. Malkin
Omar Jabri
Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, NY 10151

VIA EMAIL AND FEDERAL EXPRESS

Robert B. Breisblatt
Jeremy C. Daniel
Joanna R. Stevason
Katten Muchin Rosenmann LLP
525 West Monroe Street
Chicago, IL 60601-3693



Susan M. Coletti